Literature DB >> 21083287

Bioanalytical method requirements and statistical considerations in incurred sample reanalysis for macromolecules.

Theingi M Thway1, Chris R Macaraeg, Dominador Calamba, Laura A Brunner, Michael Eschenberg, Ramak Pourvasei, Liana Zhang, Mark Ma, Binodh Desilva.   

Abstract

BACKGROUND: Incurred sample reanalysis (ISR) is the most recent in-study validation parameter that regulatory agencies have mandated to ensure reproducibility of bioanalytical methods supporting pharmacokinetic/toxicokinetic and clinical studies. The present analysis describes five representative case studies for macromolecule therapeutics.
METHOD: Single ISR acceptance criteria (within 30% of the averaged or original concentration) and a modified Bland-Altman (BA) approach were used to assess accuracy and precision of ISR results. General concordance between the two criteria was examined using simulation studies.
RESULTS: All five methods met the ISR criteria. The results indicated that thorough method development and prestudy validation were prerequisites for a successful ISR. The overall agreement between the original and reanalyzed results as determined by BA was within 20%. Simulation studies indicated that concordance between the ISR criteria and BA was observed in 95% of the cases. Dilution factors had no significant impact on the ISR, even for C(max) samples where 1:100 or higher dilutions were used.
CONCLUSION: The current ISR acceptance criteria for macromolecules was scientifically and statistically meaningful for methods with a total error of 25% or less.

Mesh:

Substances:

Year:  2010        PMID: 21083287     DOI: 10.4155/bio.10.75

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  1 in total

1.  Assessment of incurred sample reanalysis for macromolecules to evaluate bioanalytical method robustness: effects from imprecision.

Authors:  Theingi M Thway; Michael Eschenberg; Dominador Calamba; Chris Macaraeg; Mark Ma; Binodh DeSilva
Journal:  AAPS J       Date:  2011-04-03       Impact factor: 4.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.